SCS signs UK stem cell deal with Pfizer
UK-based Stem Cell Sciences has signed a master service agreement of up to five years with global drug giant Pfizer. Under the terms of the deal, SCS will provide research services, cell lines, media and reagents to support Pfizer's R&D efforts in the field of stem cell research in the UK.
Pfizer UK's chief scientific officer, Ruth McKernan, said: "while there is still a lot to understand about how stem cells can be used therapeutically, we believe it is one of the most promising areas of scientific research. Building successful partnerships with companies such as Stem Cell Sciences will be important for us."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze